{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:05:23Z","timestamp":1791857123720,"version":"4.3.4"},"reference-count":22,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Ifosfamide (IFA) is a powerful chemotherapeutic drug that is active against a variety of paediatric malignancies. However, renal toxicities such as haemorrhagic cystitis and Fanconi syndrome are major hazards that hinder its use in clinical practice. The authors present a case of a patient treated for Wilms\u2019 tumour with IFA who developed rickets with Fanconi syndrome. Patients undergoing IFA treatment must be carefully monitored for the development of iatrogenic complications. Recent studies have improved our understanding of the underlying pathomechanism of IFA induced Fanconi syndrome, and selective renal protection against during chemotherapy with IFA may be possible soon.<\/jats:p>","DOI":"10.1136\/bcr.10.2011.4950","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T11:23:48Z","timestamp":1324380228000},"page":"bcr1020114950","source":"Crossref","is-referenced-by-count":17,"title":["Ifosfamide induced Fanconi syndrome: Table 1"],"prefix":"10.1136","volume":"2011","author":[{"given":"Samantha","family":"Buttemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith K","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,12,20]]},"reference":[{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.1","first-page":"S180","article-title":"Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.","volume":"31","author":"Bramwell","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.2","first-page":"501","article-title":"Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.","volume":"63","author":"Scheef","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.1993.11.1.173","article-title":"Ifosfamide, mesna, and nephrotoxicity in children.","volume":"11","author":"Skinner","year":"1993","journal-title":"J Clin Oncol"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03480-0"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.5","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1214"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1200\/JCO.1991.9.8.1495","article-title":"Ifosfamide, Fanconi\u2019s syndrome, and rickets.","volume":"9","author":"Pratt","year":"1991","journal-title":"J Clin Oncol"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.7","doi-asserted-by":"publisher","DOI":"10.1007\/BF01959214"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.8","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50037"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000073351","article-title":"Side effects of ifosfamide.","volume":"65","author":"Klastersky","year":"2003","journal-title":"Oncology"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.1991.9.12.2177","article-title":"Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.","volume":"9","author":"Suarez","year":"1991","journal-title":"J Clin Oncol"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80557-8"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF01428392"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.13","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide.","volume":"32","author":"Van Dyk","year":"1972","journal-title":"Cancer Res"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.14","doi-asserted-by":"publisher","DOI":"10.1159\/000073350"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.15","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1994.1241"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-2333(03)00044-4"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.17","doi-asserted-by":"publisher","DOI":"10.1021\/mp100329u"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.97"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2006.07.003"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-079X.2004.00131.x"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.21","doi-asserted-by":"publisher","DOI":"10.2131\/jts.34.SP251"},{"key":"2025082801202116000_2011.dec17_1.bcr1020114950.22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/009127009903900504","article-title":"Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.","volume":"39","author":"Loebstein","year":"1999","journal-title":"J Clin Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.10.2011.4950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:20:28Z","timestamp":1756369228000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.10.2011.4950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,20]]},"references-count":22,"alternative-id":["10.1136\/bcr.10.2011.4950"],"URL":"https:\/\/doi.org\/10.1136\/bcr.10.2011.4950","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,20]]}}}